1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Objective response rate among patients with locally advanced or metastatic sarcoma treated with talimogene laherparepvec in combination with pembrolizumab: A phase 2 clinical trial
    Journal Article

    Kelly, C. M.; Antonescu, C. R.; Bowler, T.; Munhoz, R.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Dholakia, R.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma
    Journal Article

    van Brummelen, E. M. J.; Levchenko, E.; Dómine, M.; Fennell, D. A.; Kindler, H. L.; Viteri, S.; Gadgeel, S.; López, P. G.; Kostorov, V.; Morgensztern, D.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save
  • Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Journal Article

    Shapiro, G. I.; LoRusso, P.; Kwak, E.; Pandya, S.; Rudin, C. M.; Kurkjian, C.; Cleary, J. M.; Pilat, M. J.; Jones, S.; de Crespigny, A.; more...
    Investigational New Drugs (2020)

    Fulltext@MSK | Save
  • Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
    Journal Article

    Uemura, M.; Tomita, Y.; Miyake, H.; Hatakeyama, S.; Kanayama, H. O.; Numakura, K.; Takagi, T.; Kato, T.; Eto, M.; Obara, W.; more...
    Cancer Science (2020)

    Fulltext@MSK | Save
  • Symptom burden among older breast cancer survivors: The Thinking and Living With Cancer (TLC) study
    Journal Article

    Mandelblatt, J. S.; Zhai, W.; Ahn, J.; Small, B. J.; Ahles, T. A.; Carroll, J. E.; Denduluri, N.; Dilawari, A.; Extermann, M.; Graham, D.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: Interim results from a multicentre, open-label, phase 1b study
    Journal Article

    Sequist, L. V.; Han, J. Y.; Ahn, M. J.; Cho, B. C.; Yu, H.; Kim, S. W.; Yang, J. C. H.; Lee, J. S.; Su, W. C.; Kowalski, D.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
    Journal Article

    Mamoor, M.; Postow, M. A.; Lavery, J. A.; Baxi, S. S.; Khan, N.; Mao, J. J.; Rogak, L. J.; Sidlow, R.; Thom, B.; Wolchok, J. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma
    Review

    Moffat, G. T.; O’Reilly, E. M.
    Clinical Advances in Hematology & Oncology (2020)

    Fulltext@MSK | Save
  • Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation
    Review

    Athauda, A.; Fong, C.; Lau, D. K.; Javle, M.; Abou-Alfa, G. K.; Morizane, C.; Steward, K.; Chau, I.
    Cancer Treatment Reviews (2020)

    Fulltext@MSK | Save